Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Aurora Spine slightly increases revenue and improves gross margin in Q1 2026

Aurora Spine reported Q1 2026 revenue of $4.44 million (+0.4% year‑on‑year) with a significantly improved gross profit margin of 62.6% (up 460 basis points). Net loss narrowed 42% to $203,000, and EBITDAC was positive at $107,000. The stock fell 2.04% to $0.245 after the results. The company plans to expand its sales team by 50% and expects growth from the launch of SiLO-X in the second half of the year. » Mere på de.investing.com
Aurora Spine reports record revenue of $5.02 million in Q4 2025

Aurora Spine posted record revenue of $5.02 million in Q4 2025, up 14% sequentially and 6.8% year-over-year. Gross profit margin improved to 62.4% and net loss narrowed to $41,000 from $653,000 in the year-ago quarter. ZIP and SiLO contributed 60% of revenue; EBITDAC rose to $301,000. For 2026, management expects growth from DEXA technology, notably the DEXA-L implant, and plans to expand the sales team by 50%. » Mere på de.investing.com
Aurora Spine reports Q3 2025 revenue decline despite product launches

Aurora Spine recorded a 7.1% revenue decline in the third quarter of 2025 to USD 4.43 million, with a net loss of USD 842,000 and cash on hand of just under USD 700,000. Gross margin improved slightly to 60.9% and operating expenses fell to USD 2.81 million. The company launched the facet pain implant Hydra ARO and the anterior lumbar fusion system DEXA L, is targeting monthly revenue above USD 1.4 million, and plans to expand the DEXA L kits in 2026. The stock fell 6.67% after the results were released. » Mere på de.investing.com
Aurora Spine Corporation reports 10.2% revenue growth for Q2 2025 and remains unprofitable

Aurora Spine Corporation increased revenue in the second quarter of 2025 by 10.2% to $4.5 million, with an improved gross margin of 62.2%, but still posted a net loss of $199,000. The company is introducing new products such as Hydra Arrow and DEXA L, plans to expand its sales team, and expects further growth in H2 2025 driven by rising demand for minimally invasive spinal procedures. Management expressed optimism for the second half of the year but flagged risks from competition and macroeconomic uncertainty. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde AURORA SPINE CORP. en omsætning på 3,12 mio. € og et nettoresultat på -712,85 t €

(EUR)	juni 2026	YoY
Omsætning	3,12 mio.	18,13 %
Bruttofortjeneste	410,48 t	82,72 %
Nettoresultat	-712,85 t	322,73 %
EBITDA	-460,61 t	541,45 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	4,43 mio. €
Antal aktier	78,09 mio.
Højeste/laveste i 52 uger	0,21 € - 0,0567 €
Udbytte	Nej
Beta	-0,56
P/E (PE Ratio)	-4,32
PEG (PEG Ratio)	0,04
K/I (PB Ratio)	1,84
P/S (PS Ratio)	0,30

Virksomhedsprofil

Aurora Spine Corporation udvikler og distribuerer gennem sit datterselskab, Aurora Spine, Inc., minimalt invasive interspinøse fusionssystemer og -udstyr i Canada. Virksomheden tilbyder interspinøse processus-lumbale fusionsenheder, såsom ZIP, ZIP ULTRA, ZIP LP og ZIP-51, til patienter med degenerative discussygdomme; samt titanbelagte interbody-bure af polyetheretherketon, som sikrer afstand og stabilitet mellem hvirvlerne, mens knoglen gror sammen og fusionsprocessen fuldendes. Virksomheden leverer også steriltpakkede spinale infusionsimplantater belagt med titanplasmasprøjtning til knoglevækst, samt interbody-produkter såsom EOS, VOX, Echo, Echo SD og EchoXL til den lumbale del af rygsøjlen og discovery til cervikale indgreb. Derudover tilbyder virksomheden SOLO, en 3D-printet anterior lumbal interbody-fusionsenhed til stand-alone brug, som er et integreret plade- og afstandssystem, der hjælper med at bevare den naturlige anatomiske profil, samt giver støtte og stabilitet til rygsøjlen; og SiLo, en posterior fusionsenhed til sacroiliakalleddet. Endvidere tilbyder virksomheden DEXA-C, et cervikalt interbody-system, som er en porøs 3D-printet intervertebral fusionsenhed, der indeholder gitterstrukturer med lav, medium eller høj densitet, så den kan tilpasses patienters knoglekvalitet. Aurora Spine Corporation blev stiftet i 2013 og har hovedkontor i Toronto, Canada.